Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.27+0.12 (+1.47%)
Close on Nov 18, 2026Market cap $288.48MP/E –Yield –
Benitec Biopharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Benitec Biopharma's free cash flow for the twelve months ending Jun 30, 2026 was -$16.62M. For fiscal 2026 it was -$16.62M. The highest annual figure on record is $4.39M in fiscal 2019.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$16.62M | – |
| FY2025 | Jun 30, 2025 | -$23.61M | – |
| FY2024 | Jun 30, 2024 | -$19.58M | – |
| FY2023 | Jun 30, 2023 | -$18.01M | – |
| FY2022 | Jun 30, 2022 | -$15.91M | – |
| FY2021 | Jun 30, 2021 | -$13.05M | – |
| FY2020 | Jun 30, 2020 | -$7.63M | -274.0% |
| FY2019 | Jun 30, 2019 | $4.39M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$5.02M | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$4.47M | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$8.21M | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$3.09M | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$3.29M | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$4.10M | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$4.87M | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$3.42M | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$3.34M | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$4.28M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$5.02M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$2.00M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$3.50M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$2.53M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$3.16M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$769.00K | – |
See a number that looks wrong?